JP6959663B2 - Ｆｇｆｒ阻害剤としての複素環化合物 - Google Patents
Ｆｇｆｒ阻害剤としての複素環化合物 Download PDFInfo
- Publication number
- JP6959663B2 JP6959663B2 JP2019529309A JP2019529309A JP6959663B2 JP 6959663 B2 JP6959663 B2 JP 6959663B2 JP 2019529309 A JP2019529309 A JP 2019529309A JP 2019529309 A JP2019529309 A JP 2019529309A JP 6959663 B2 JP6959663 B2 JP 6959663B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- group
- pharmaceutically acceptable
- bond
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *=Nc(cccc1)c1N Chemical compound *=Nc(cccc1)c1N 0.000 description 1
- VTYONRIOLDTSGB-UHFFFAOYSA-N C1C2=C[I]=NC=C2OC1 Chemical compound C1C2=C[I]=NC=C2OC1 VTYONRIOLDTSGB-UHFFFAOYSA-N 0.000 description 1
- UHPPFIOSYWGDJO-UHFFFAOYSA-N CC#CC(N(CC1)CC1c1nc(C#Cc2cc(OC)cc(OC)c2)c2[n]1ccnc2N)=O Chemical compound CC#CC(N(CC1)CC1c1nc(C#Cc2cc(OC)cc(OC)c2)c2[n]1ccnc2N)=O UHPPFIOSYWGDJO-UHFFFAOYSA-N 0.000 description 1
- VCVACUXPDLCBHF-UHFFFAOYSA-N CN1c(cccc2)c2OC1 Chemical compound CN1c(cccc2)c2OC1 VCVACUXPDLCBHF-UHFFFAOYSA-N 0.000 description 1
- LVOFAVDBRPKDCK-UHFFFAOYSA-N N=Cc1c(N=[IH])[o]cc1 Chemical compound N=Cc1c(N=[IH])[o]cc1 LVOFAVDBRPKDCK-UHFFFAOYSA-N 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N c1c[nH]c2c1cccc2 Chemical compound c1c[nH]c2c1cccc2 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N c1cc2ccncc2cc1 Chemical compound c1cc2ccncc2cc1 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- KTRNSGQADWUBMH-UHFFFAOYSA-N c1n[nH]c2c1N=[I]C=C2 Chemical compound c1n[nH]c2c1N=[I]C=C2 KTRNSGQADWUBMH-UHFFFAOYSA-N 0.000 description 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N c1nc(cccc2)c2[s]1 Chemical compound c1nc(cccc2)c2[s]1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610647295.0 | 2016-08-09 | ||
| CN201610647295.0A CN107698593A (zh) | 2016-08-09 | 2016-08-09 | 作为fgfr抑制剂的杂环化合物 |
| PCT/CN2017/094620 WO2018028438A1 (zh) | 2016-08-09 | 2017-07-27 | 作为fgfr抑制剂的杂环化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019524883A JP2019524883A (ja) | 2019-09-05 |
| JP2019524883A5 JP2019524883A5 (https=) | 2020-07-16 |
| JP6959663B2 true JP6959663B2 (ja) | 2021-11-02 |
Family
ID=61162708
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019529309A Expired - Fee Related JP6959663B2 (ja) | 2016-08-09 | 2017-07-27 | Ｆｇｆｒ阻害剤としての複素環化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10752631B2 (https=) |
| EP (1) | EP3498706A4 (https=) |
| JP (1) | JP6959663B2 (https=) |
| KR (1) | KR20190035870A (https=) |
| CN (2) | CN107698593A (https=) |
| CA (1) | CA3032921A1 (https=) |
| WO (1) | WO2018028438A1 (https=) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3634449A4 (en) | 2017-05-08 | 2021-03-17 | Gritstone Oncology, Inc. | ALPHAVIRUS NEOANTIGEN VECTORS |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| EP3969442A4 (en) * | 2019-05-17 | 2023-08-02 | Kinnate Biopharma Inc. | FIBROBLAST GROWTH FACTOR RECEPTOR KINASE INHIBITORS |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US11345681B1 (en) | 2020-06-05 | 2022-05-31 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| CN116096707A (zh) * | 2020-06-05 | 2023-05-09 | 金耐特生物制药公司 | 成纤维细胞生长因子受体激酶的抑制剂 |
| CN116438308A (zh) | 2020-08-06 | 2023-07-14 | 磨石生物公司 | 多表位疫苗盒 |
| CN112480109B (zh) * | 2020-11-16 | 2022-04-01 | 浙江大学 | 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途 |
| AU2022206989A1 (en) * | 2021-01-12 | 2023-08-24 | Beijing Innocare Pharma Tech Co., Ltd. | Process for preparing (s)-1-(1-acryloylpyrrolidin-3-yl)-3-((3,5-dimethoxyphenyl) ethynyl)-5-(methylamino)-1h-pyrazole-4-carboxamide |
| CN114853739B (zh) * | 2021-02-03 | 2023-09-22 | 药雅科技(上海)有限公司 | 一种炔代吡嗪类fgfr抑制剂及其制备方法和用途 |
| CN115043832B (zh) * | 2021-03-08 | 2023-08-22 | 药雅科技(上海)有限公司 | 一种fgfr抑制剂炔代杂环类化合物及其制备方法和用途 |
| WO2024083111A1 (zh) * | 2022-10-18 | 2024-04-25 | 首药控股(北京)股份有限公司 | 一种新型杂环化合物 |
| AU2024241633A1 (en) | 2023-03-30 | 2025-11-06 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| TW202508595A (zh) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | 用於ｒａｓ相關疾病或病症之組合療法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202547461A (zh) | 2024-05-17 | 2025-12-16 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200738725A (en) * | 2006-01-25 | 2007-10-16 | Osi Pharm Inc | Unsaturated mTOR inhibitors |
| MY171055A (en) | 2012-01-19 | 2019-09-23 | Taiho Pharmaceutical Co Ltd | 3,5-disubstituted alkynylbenzene compound and salt thereof |
| US20160031888A1 (en) * | 2013-03-13 | 2016-02-04 | Boston Biomedical, Inc. | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
| US10124003B2 (en) | 2013-07-18 | 2018-11-13 | Taiho Pharmaceutical Co., Ltd. | Therapeutic agent for FGFR inhibitor-resistant cancer |
| AU2014291161B2 (en) * | 2013-07-18 | 2018-04-26 | Taiho Pharmaceutical Co., Ltd. | Antitumor drug for intermittent administration of FGFR inhibitor |
| CN104341425B (zh) * | 2013-08-08 | 2018-11-02 | 上海医药集团股份有限公司 | 氘代乙炔衍生物、其药物组合物及应用 |
| KR102272792B1 (ko) * | 2013-09-30 | 2021-07-05 | 광저우 이노케어 파마 테크 씨오., 엘티디. | Ｂｔｋ의 치환된 니코틴이미드 저해제 및 그의 제조 방법 및 암, 염증 및 자가면역 질환에의 용도 |
| ES2904544T3 (es) * | 2014-08-19 | 2022-04-05 | Shanghai Haihe Pharmaceutical Co Ltd | Compuestos de indazol como inhibidores de la cinasa FGFR, preparación y uso de los mismos |
-
2016
- 2016-08-09 CN CN201610647295.0A patent/CN107698593A/zh active Pending
-
2017
- 2017-07-27 CN CN201780045675.XA patent/CN109715626B/zh active Active
- 2017-07-27 CA CA3032921A patent/CA3032921A1/en active Pending
- 2017-07-27 EP EP17838568.8A patent/EP3498706A4/en not_active Withdrawn
- 2017-07-27 KR KR1020197006637A patent/KR20190035870A/ko not_active Ceased
- 2017-07-27 WO PCT/CN2017/094620 patent/WO2018028438A1/zh not_active Ceased
- 2017-07-27 US US16/324,189 patent/US10752631B2/en not_active Expired - Fee Related
- 2017-07-27 JP JP2019529309A patent/JP6959663B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP3498706A1 (en) | 2019-06-19 |
| US10752631B2 (en) | 2020-08-25 |
| WO2018028438A1 (zh) | 2018-02-15 |
| EP3498706A4 (en) | 2020-02-26 |
| US20190177333A1 (en) | 2019-06-13 |
| CA3032921A1 (en) | 2018-02-15 |
| JP2019524883A (ja) | 2019-09-05 |
| KR20190035870A (ko) | 2019-04-03 |
| CN109715626B (zh) | 2022-04-26 |
| CN107698593A (zh) | 2018-02-16 |
| CN109715626A (zh) | 2019-05-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6959663B2 (ja) | Ｆｇｆｒ阻害剤としての複素環化合物 | |
| RU2742485C2 (ru) | Гетероциклическое соединение, используемое как ингибитор fgfr | |
| TWI725266B (zh) | Fgfr4抑制劑、其製備方法與藥學上的應用 | |
| WO2019223766A1 (zh) | 一种fgfr抑制剂、其制备方法和在药学上的应用 | |
| CN102686591B (zh) | 酞嗪酮类衍生物、其制备方法及其在医药上的应用 | |
| WO2021143701A1 (zh) | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 | |
| EP2086981A1 (en) | Compounds for inhibiting mitotic progression | |
| WO2017162007A1 (zh) | 芳香族酰胺类衍生物、其制备方法及其在医药上的应用 | |
| EP3157925A1 (en) | Imidazo-pyridazne derivatives as casein kinase 1 delta/epsilon inhibitors | |
| CN107021963A (zh) | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 | |
| WO2020063788A1 (zh) | Fgfr4抑制剂及其应用 | |
| CN106831812A (zh) | 含联芳基酰胺结构的杂环并嘧啶或吡嗪类化合物及其应用 | |
| WO2019223548A1 (zh) | 3-吲唑啉酮类化合物、其制备方法及其在医药学上的应用 | |
| JP2023530768A (ja) | Ｆｇｆｒおよびその突然変異阻害剤、その製造方法と応用 | |
| JP7152794B2 (ja) | Ｆｇｆｒ阻害剤、その製造方法および応用 | |
| CN114057749B (zh) | 不可逆炔类杂环化合物fgfr抑制剂的制备方法和用途 | |
| CN120943837A (zh) | 作为酪氨酸激酶抑制剂的杂环化合物 | |
| CN110272415A (zh) | 3,4-二氢吡啶并[4,3-d]嘧啶类衍生物及其制备方法和用途 | |
| HK40002365A (en) | Heterocyclic compound as fgfr inhibitor | |
| HK40042846B (zh) | Fgfr4抑制剂及其应用 | |
| HK1245261A1 (zh) | 作为fgfr抑制剂的杂环化合物 | |
| CN107652273A (zh) | 嘧啶类衍生物及其制备方法和应用 | |
| HK40009843A (en) | Fgfr inhibitor and application thereof | |
| HK1258833A1 (zh) | 作为fgfr抑制剂的杂环化合物 | |
| HK1258833B (zh) | 作为fgfr抑制剂的杂环化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200605 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200605 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210323 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210511 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210914 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211001 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6959663 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| LAPS | Cancellation because of no payment of annual fees |